Carrot juice for preventing colorectal cancer in high-risk patients
Polyp Prophylactic Properties of Polyacetylenes in Patients With Previous Polypectomy
This study is testing if drinking carrot juice every day can help prevent colorectal cancer from coming back in patients who are at high risk after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Odense University Hospital Academic / other |
| Drugs / interventions | Methotrexate |
| Locations | 1 site (Odense) |
| Trial ID | NCT06335420 on ClinicalTrials.gov |
What this trial studies
This prospective randomized double-blinded study aims to evaluate the prophylactic effects of carrot juice rich in polyacetylenes on patients who have undergone resection of high-risk colorectal adenomas. Participants will consume 100 ml of either active carrot juice or placebo daily for one year, while their compliance will be monitored through diaries. The study will compare the incidence and growth of recurrent adenomas between the two groups to determine if the carrot juice significantly reduces neoplastic transformation. The trial is conducted across multiple centers in Denmark and Sweden.
Who should consider this trial
Good fit: Ideal candidates are patients who have had a resection of adenomas larger than 20 mm and are classified as high-risk for colorectal cancer.
Not a fit: Patients with multiple small polyps, severe comorbidities, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary intervention to reduce the risk of colorectal cancer in high-risk patients.
How similar studies have performed: While the use of dietary interventions in cancer prevention is a growing field, this specific approach using carrot juice is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Any type of resection for adenomas larger than 20 mm in size (endoscopically evaluated) or endoscopically resected T1 cancers. 2. Acceptance of the treatment and follow-up program. 3. Capability to understand and follow the instructions. Exclusion Criteria: 1. Patients allocated to "high-risk" group because of many small polyps (\>4). 2. Pregnancy. 3. Known relevant allergies. 4. Chronic consumption of COX (cyclooxygenase) inhibitors (Aspirin, Celecoxib, Ibuprofen, Diclofenac, Ketoprofen, Ketorolac, Indometacin, Naproxen, Piroxicam) or immunosuppressive agents (Methotrexate, Azathioprine or glucocorticoids). 5. Patients with different neoplastic disease under treatment (Chemo-/Radio-/Imunotherapy). 6. Severe comorbidity NYHA III-IV. 7. Lynch syndrome.
Where this trial is running
Odense
- Department of Surgery, Odense University Hospital — Odense, Denmark (Recruiting)
Study contacts
- Principal investigator: Gunnar Baatrup, Professor — OUH og Svendborg Sygehus
- Study coordinator: Gunnar Baatrup, Professor
- Email: Gunnar.Baatrup@rsyd.dk
- Phone: +4520575154
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.